Comparison of the GPVI inhibitors losartan and honokiol. (17th February 2020)

• Record Type: Journal Article
• Authors: Onselaer, Marie-Blanche; Nagy, Magdolna; Pallini, Chiara; Pike, Jeremy A; Perrella, Gina; Quintanilla, Lourdes Garcia; Eble, Johannes A; Poulter, Natalie S.; Heemskerk, Johan W.M.; Watson, Steve P
• Is Part Of: Platelets. Volume 31:Number 2(2020)
• Page Start: 187
• Page End: 197
• Publication Date: 2020-02-17
• Subjects: CLEC-2 -- GPVI -- GPVI -- honokiol -- losartan -- platelets; Blood platelets -- Periodicals; Blood Platelets -- Periodicals; 615.39
• DOI: 10.1080/09537104.2019.1585526
• Languages: English
• ISSNs: 0953-7104

Abstract

Abstract: Losartan and honokiol are small molecules which have been described to inhibit aggregation of platelets by collagen. Losartan has been proposed to block clustering of GPVI but not to affect binding of collagen. Honokiol has been reported to bind directly to GPVI but only at a concentration that is three orders of magnitude higher than that needed for inhibition of aggregation. The mechanism of action of both inhibitors is so far unclear. In the present study, we confirm the inhibitory effects of both agents on platelet aggregation by collagen and show that both also block the aggregation induced by the activation of CLEC-2 or the low affinity immune receptor FcγRIIa at similar concentrations. For GPVI and CLEC-2, this inhibition is associated with a reduction in protein tyrosine phosphorylation of multiple proteins including Syk. In contrast, on a collagen surface, spreading of platelets and clustering of GPVI (measured by single molecule localisation microscopy) was not altered by losartan or honokiol. Furthermore, in flow whole-blood, both inhibitors suppressed the formation of multi-layered platelet thrombi at arteriolar shear rates at concentrations that hardly affect collagen-induced platelet aggregation in platelet rich plasma. Together, these results demonstrate that losartan and honokiol have multiple effects on platelets which should be considered in the use of these compounds as anti-platelet agents.